With COVID-19 pandemic outbreak and reduced outdoor time for children, the risk for childhood myopia has increased many folds.
Young children (around 6 years of age) require higher concentrations (0.05%) of atropine to achieve similar reductions in myopia progression as older children (8-10 years of age) on lower concentrations (0.025% or 0.01%), since myopia progression is age dependent and younger myopic kids tend to progress faster than older children.
A randomized Low concentration Atropine for Myopia Progression (LAMP study) showed that younger age was the only factor associated with spherical equivalent progression and axial length elongation in all treatment groups, and titrating atropine concentration according to age shows good tolerance and better treatment response.
Read more – https://www.medscape.com/viewarticle/944375